Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

COVID vaccine resistance in underrepresented communities

Amisha Wallia, MD
Conditions
December 25, 2020
Share
Tweet
Share

Despite advances in the science of diabetes, including a huge armory of new drugs, over 34.2 million people still suffer. More than 88 million adults are at risk for diabetes, disproportionately affecting Black and brown communities. Individuals with diabetes, high blood pressure, and heart disease are also the same people at the highest risk of contracting and dying of COVID-19. Despite being overrepresented in the virus’s terrible complications, we are still not reaching those communities as we should.

While vaccine acceptability is rising, it is still shockingly low in Black communities. There are rational reasons for this based on how African Americans historically have been mistreated at times by the scientific community and the previously documented medical bias. Still, it’s important to engender confidence in a vaccine that could start to address the uneven and unfair impact of the coronavirus on underserved communities as a whole.

There’s been a huge push from the scientific community to ensure their enrollment into clinical COVID-19 vaccine trials. Many scientists, such as myself, are ecstatic to see a concerted effort to finally minimize disparities in the scientific process from the very beginning with diverse leadership and thoughtful planning. One example of success in this area is Moderna’s 30,000-person COVID-19 vaccine clinical trial, of which a third includes underrepresented individuals. Nothing says “this solution was made for you” more than intentional inclusion in the trial phase.

As a diabetes doctor and scientist, I am extremely worried about those who are resistant to taking vaccines. Each week I go to my clinic, knowing there will be pushback to life-extending advice I give my patients suffering from diabetes. It feels like this could be a losing battle if we don’t pay attention and adapt our messaging and our strategy.

During every clinic, I work harder and harder to convince my patients to take their medications and trust me and the medical system. It doesn’t help that our systems move so slowly: Time spent on pre-authorizations and approvals is longer and longer. Yet blood pressure control, glucose control, blood, and smoking rates in diabetes are worse than ever. Insulin, a life-saving medication with alarmingly higher costs, still causes many to have a deep distrust in starting this medication.

The secret rule of 50/50 is alive and well: 50% of people take their medications generally 50% of the time. The reasons are complex and deeply rooted and are not just patient-related (literacy, self-efficacy). Providers and health systems are implicated here due to communication issues, prescribing patterns, access, and time limitations.

We seemingly have not learned from our previous failures, and we keep forgetting about the “prevention paradox,” which prioritizes individual health over population health. We haven’t been paying attention to the root causes of chronic conditions like diabetes and have been spending way too much money on ventilators and not enough on personal protective equipment.

We must reach our communities where they are, surrounded by people and institutions they trust. Blast emails and high language will not work here. We need trusted community members demonstrating and showing the vaccine is safe and explaining why it is safe. We need researchers from all walks of life who have participated in this research to explain why this vaccine came out so fast. We need field health educators and diverse outreach groups to take up the cause. We need to be nimble and adapt as needed, and we need to track the safety of the vaccine in all communities.

But as a diabetes researcher for years, I am also hopeful.

I’ve worked with all types of stakeholders, government officials, pharmaceutical companies, payors, institutions, other health care providers, and nonprofits wanting what’s best for these patients and allocating real resources to improve research and care delivery. I have seen a change in those at the table, including more women, such as myself, and more underrepresented people.

According to Dr. Rosalind Ramsey-Goldman, a bright spot on this front is community-academic partnerships (CAP), and where health systems work with community leaders to understand decision-making regarding participation in clinical trials a colleague who has participated in these initiatives. Using a playbook that incorporates their insights, community leaders offer plain-spoken language to community members about key components of clinical trials, so neighborhoods have the confidence to test new treatments.

There have been breakthrough scientific drug advancements, unheard of in other industries, with several new classes of medications — more in the last 10 years than the previous 30. My husband jokes that you cannot watch a football game without seeing at least two new diabetes medication commercials per half.

These next few months are absolutely critical for our future as a community and a society.

ADVERTISEMENT

I still go to my clinic every week and fight the good fight, knowing if I can convince one patient to go on insulin or get one insurer to cover a newer diabetes medication, I am winning the battle one patient at a time. And I am eager to see the systems above me change to help my patients more. I hope my deepest fear about vaccine acceptance dissipates and that our great scientific breakthrough doesn’t become our greatest defeat — 2020 has been hard enough.

This article is dedicated to the family, memory, and work of Dr. Nicholas V. Emanuele, a diabetes physician and researcher.

Amisha Wallia is an endocrinologist.

Image credit: Shutterstock.com

Prev

The 12 days of COVID

December 25, 2020 Kevin 1
…
Next

My first end-of-life conversation

December 25, 2020 Kevin 1
…

Tagged as: COVID, Infectious Disease

Post navigation

< Previous Post
The 12 days of COVID
Next Post >
My first end-of-life conversation

ADVERTISEMENT

Related Posts

  • Major medical groups back mandatory COVID vaccine for health care workers

    Molly Walker
  • Is it time for a true federal COVID vaccine mandate?

    Shetal Shah, MD
  • The COVID vaccine selfie: The caption matters as much as the picture

    Alicia Billington, MD, PhD
  • COVID-19 divides and conquers

    Michele Luckenbaugh
  • Where’s the big COVID data?

    Anuradha Kolluru, MD and Rakesh Lattupalli, MD
  • COVID-19 vaccine and disinformation: How health care providers can leverage social media to combat this trend

    Emmanuel Ohuabunwa, MD, MBA, Victor Agbafe, and Onyema Ogbuagu, MD

More in Conditions

  • Inside the high-stakes world of neurosurgery

    Isaac Yang, MD
  • Why I left the clinic to lead health care from the inside

    Vandana Maurya, MHA
  • One injection dropped LDL by 69 percent. Should we celebrate?

    Larry Kaskel, MD
  • Does cycling hurt male fertility?

    Martina Ambardjieva, MD, PhD
  • How community and buses saved my retirement

    Raymond Abbott
  • How changing your self-talk can transform your entire life

    Faust Ruggiero
  • Most Popular

  • Past Week

    • Why your clinic waiting room may affect patient outcomes

      Ziya Altug, PT, DPT and Shirish Sachdeva, PT, DPT | Conditions
    • The backbone of health care is breaking

      Grace Yu, MD | Physician
    • Nuclear verdicts and rising costs: How inflation is reshaping medical malpractice claims

      Robert E. White, Jr. & The Doctors Company | Policy
    • How new loan caps could destroy diversity in medical education

      Caleb Andrus-Gazyeva | Policy
    • Why transplant equity requires more than access

      Zamra Amjid, DHSc, MHA | Policy
    • The ethical crossroads of medicine and legislation

      M. Bennet Broner, PhD | Conditions
  • Past 6 Months

    • Health equity in Inland Southern California requires urgent action

      Vishruth Nagam | Policy
    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • Why primary care needs better dermatology training

      Alex Siauw | Conditions
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • Why AI in health care needs stronger testing before clinical use [PODCAST]

      The Podcast by KevinMD | Podcast
    • How AI is reshaping preventive medicine

      Jalene Jacob, MD, MBA | Tech
    • How transplant recipients can pay it forward through organ donation

      Deepak Gupta, MD | Physician
    • Inside the high-stakes world of neurosurgery

      Isaac Yang, MD | Conditions
    • Why I left the clinic to lead health care from the inside

      Vandana Maurya, MHA | Conditions
    • How doctors can think like CEOs [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Why your clinic waiting room may affect patient outcomes

      Ziya Altug, PT, DPT and Shirish Sachdeva, PT, DPT | Conditions
    • The backbone of health care is breaking

      Grace Yu, MD | Physician
    • Nuclear verdicts and rising costs: How inflation is reshaping medical malpractice claims

      Robert E. White, Jr. & The Doctors Company | Policy
    • How new loan caps could destroy diversity in medical education

      Caleb Andrus-Gazyeva | Policy
    • Why transplant equity requires more than access

      Zamra Amjid, DHSc, MHA | Policy
    • The ethical crossroads of medicine and legislation

      M. Bennet Broner, PhD | Conditions
  • Past 6 Months

    • Health equity in Inland Southern California requires urgent action

      Vishruth Nagam | Policy
    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • Why primary care needs better dermatology training

      Alex Siauw | Conditions
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • Why AI in health care needs stronger testing before clinical use [PODCAST]

      The Podcast by KevinMD | Podcast
    • How AI is reshaping preventive medicine

      Jalene Jacob, MD, MBA | Tech
    • How transplant recipients can pay it forward through organ donation

      Deepak Gupta, MD | Physician
    • Inside the high-stakes world of neurosurgery

      Isaac Yang, MD | Conditions
    • Why I left the clinic to lead health care from the inside

      Vandana Maurya, MHA | Conditions
    • How doctors can think like CEOs [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...